Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 177,849 | N/A | N/A | N/A | 97,594 |
| Other current assets | 0 | 0 | 0 | 0 | 5,467 |
| TOTAL | $187,797 | $N/A | $N/A | $N/A | $103,061 |
| Non-Current Assets | |||||
| PPE Net | 13,369 | N/A | N/A | N/A | 2,161 |
| Other Non-Current Assets | 17,752 | 0 | 0 | 0 | 34 |
| TOTAL | $31,121 | $N/A | $N/A | $N/A | $2,195 |
| Total Assets | $218,918 | $N/A | $N/A | $N/A | $105,205 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,314 | 0 | 0 | 0 | 902 |
| Accrued Expenses | 6,590 | N/A | N/A | N/A | 2,468 |
| TOTAL | $16,623 | $N/A | $N/A | $N/A | $3,857 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 652 | 0 | 0 | 0 | 0 |
| TOTAL | $12,923 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $29,546 | $N/A | $N/A | $N/A | $3,857 |
| Shareholders' Equity | |||||
| Common Shares | 6 | N/A | N/A | N/A | 14 |
| Retained earnings | -58,012 | N/A | N/A | N/A | -24,813 |
| Other shareholders' equity | 12,322 | 0 | 0 | 0 | 8,189 |
| TOTAL | $189,372 | $N/A | $N/A | $N/A | $101,348 |
| Total Liabilities And Equity | $218,918 | $0 | $0 | $0 | $105,205 |